FactorPad
Build a Better Process

Stock Risk Measures for Jazz Pharmaceuticals Plc

A quantitative factor review as of December 31, 2020.
  1. Company Info - Description, identity and sector data.
  2. Share Data - Stock earnings and key dates.
  3. Market Risk - Beta, size, liquidity and momentum measures.
  4. Financial Risk - Earnings and dividends.
face pic by Paul Alan Davis, CFA
Updated: January 03, 2021
See how we arrive at an overall risk score of 42 for JAZZ below.

/ factorpad.com / stocks / f82txf.html


An ad-free and cookie-free webpage by FactorPad


JAZZ Risk Report

Overview

Our quantitative data points are meant to provide a high-level understanding of factors in equity risk models for Jazz Pharmaceuticals Plc. Portfolio managers use these models to forecast risk, optimize portfolios and review performance.

We show how JAZZ stock compares to 2,000+ US-based stocks, and to peers in the Manufacturing sector and Pharmaceutical Preparation Manufacturing industry.

Please do not consider this data as investment advice. Data is downloaded from sources we deem reliable, but errors may occur.

Company Info

Business Description

Company logo Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem , the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid . In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea . In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.

Identity

Sector and Industry

Share Data

Shares

Earnings and Dividends

Market Risk Measures

Many of the following risk metrics are standardized and transformed into quantitative factors in institutional-level risk models.

Rankings below represent percentiles from 1 to 100, with 1 being the lowest rating of risk.

Systematic Risk

Stocks with higher beta exhibit higher sensitivity to the ups and downs in the market. (↑↑)

Company Size

Stocks with higher market capitalization often have lower risk. (↑↓)

Trading Liquidity

Higher average daily dollar volume over the past 30 days implies lower liquidity risk. (↑↓)

Price Momentum

Higher price momentum stocks, aka recent winners, equate to lower risk for many investors. (↑↓)

Financial Risk Measures

Style risk factors often include measures of profitability and payout levels.

Earnings Yield

Companies with higher earnings generally provide lower risk. (↑↓)

Dividend Yield

Companies with higher dividend yields, if sustaintable, are perceived to have lower risk. (↑↓)

/ factorpad.com / stocks / f82txf.html


JAZZ stock risk
JAZZ PHARMACEUTICALS PLC stock beta
JAZZ risk report
JAZZ f82txf
JAZZ risk analysis
JAZZ volatility
JAZZ PHARMACEUTICALS PLC credit risk
JAZZ liquidity risk
JAZZ leverage
JAZZ valuation
JAZZ systematic risk
JAZZ specific risk
JAZZ PHARMACEUTICALS PLC volatility
JAZZ analysis
JAZZ financial ratio

This is a new resource, spread the word, tell a friend